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OBJECTIVES This study was designed to analyze the association among cholesterol levels, lipid-lowering
treatment, and progression of aortic stenosis (AS) in the community.
BACKGROUND Aortic stenosis is a progressive disease for which there is no known medical treatment to
prevent or slow progression. Despite plausible pathologic mechanisms linking hypercholes-
terolemia to AS progression, clinical studies have been inconsistent and affected by referral
bias, and the role of lipid-lowering therapy is uncertain.
METHODS We determined the association between blood cholesterol levels and progression of native AS
(assessed by Doppler echocardiography at baseline and at least six months later; mean interval,
3.7  2.3 years) in a community-based study of 156 patients (age 77  12 years; 90 men).
Thirty-eight patients received statin treatment during follow-up.
RESULTS In untreated subjects, mean gradient increased from 22  12 mm Hg to 39  19 mm Hg,
and aortic valve area (AVA) decreased from 1.20  0.35 cm2 to 0.91  0.33 cm2 (both p 
0.001). The annualized change in AVA was 0.09  0.17 cm2/year (7%  13%/year).
Neither total cholesterol (r  0.01, p  0.92) nor low-density lipoprotein cholesterol (r 
0.01; p  0.88) showed a significant correlation to AS progression. Nevertheless, progression
of AS was slower in patients receiving statins compared with untreated patients (decrease in
AVA 3  10% vs.7  13% per year, respectively; p 0.04), even when adjusted for age,
gender, cholesterol, and baseline valve area (p  0.04). The association of statin treatment
with slower progression was confirmed when analysis was restricted to patients coming for a
systematic follow-up (p  0.02). The odds ratio of AS progression with statin treatment was
0.46 (95% confidence interval, 0.21 to 0.96).
CONCLUSIONS In the community, progression of AS shows no trend of association with cholesterol levels.
Statin treatment, however, is associated with slower progression, suggesting that the effects of
statin treatment on progression of AS should be pursued with appropriate clinical
trials. (J Am Coll Cardiol 2002;40:1723–30) © 2002 by the American College of
Cardiology Foundation
Aortic stenosis (AS) is common with aging and is a
progressive disease (1) for which there is no known medical
treatment. For most patients progressing to severe stenosis,
surgical intervention is required (2). New biologic insight
into development of AS suggests that infiltration (3) and
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oxidation (4) of lipoproteins are important in initiation of
the early valvular lesion. This “cholesterol hypothesis” has
generated intense interest, as it may imply a potential role of
lipid-lowering drugs in retarding disease progression (5,6).
However, human studies of the association of AS and
hyperlipidemia have been inconsistent. Some have shown a
positive association (6–11), but were balanced by others
demonstrating only a weak or absent association (12–16).
This inconsistency may be due to design issues; positive
association of cholesterol levels with AS severity was ob-
served in studies using single rather than sequential exam-
inations to determine progression (7–9), or in which pa-
tients with renal failure may have skewed results (10). These
limitations, and the referral bias to which all referral center
studies were subject, also influence evaluation of treatment
effect (6,17). There are concerns that those patients with
hyperlipidemia and progressive AS may be overrepresented
in studies, and that reasons for follow-up (progression of AS
symptoms vs. hyperlipidemia) may lead to spurious associ-
ations of lipid levels with AS progression. Therefore, further
human studies are needed, not only to ascertain AS pro-
gression and its association with lipid levels, but also to
assess treatments taken and reasons for follow-up, which
can be best defined in community-based studies. Associa-
tion between elevated cholesterol and AS progression would
support conduct of a randomized clinical trial of lipid-
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lowering drugs, particularly statins, which have proven
clinical benefits (18).
The Rochester Epidemiology Project, based in Olmsted
County, Minnesota (19), is a population-based data re-
source allowing identification of all patients with AS who
have undergone assessment by a single-core echocardio-
graphic laboratory and where reasons for evaluation and
drug treatments are consistently recorded. We performed
this community-based study to answer two specific ques-
tions: First, is AS progression in the community correlated
with cholesterol levels or other risk factors? Second, is AS
progression slower in subjects receiving lipid-lowering treat-
ment, particularly statins?
METHODS
Study population. Eligible subjects were obtained by
screening all adults (18 years) with AS in Olmsted
County, Minnesota, from January 1987 to March 2000.
Clinical, laboratory, and echocardiographic data were uti-
lized, unaltered via electronic transfer.
Eligibility criteria. Inclusion criteria were as follows: eval-
uation of native AS with Doppler aortic mean gradient
(MG) 10 mm Hg and aortic valve area (AVA) 2.0 cm2,
coinciding with cholesterol level measurement, consent to
research, and a second echocardiographic assessment of AS
separated by 6 months. The follow-up echocardiogram
was the latest performed or the last before valve surgery.
Exclusion criteria were presence of congenital heart
disease (other than bicuspid aortic valve), overt history and
echocardiographic features of rheumatic heart disease, cre-
atinine 2.0 mg/dl, lipid-lowering treatment without sta-
tin, subaortic obstruction precluding measurement of AVA,
aortic regurgitation mild, and previous aortic valve sur-
gery, repair, or decalcification.
Clinical data. Clinical data prospectively collected by at-
tending physicians included age, gender, etiology of valvular
stenosis, smoking history, and documented diagnoses of
hypertension, diabetes, and coronary disease (history of
myocardial infarction or coronary obstruction on coronary
angiography). At baseline and follow-up, symptoms, heart
rhythm, and blood pressure were recorded with prospec-
tively obtained laboratory results for serum total cholesterol
(TC), triglycerides, high-density lipoprotein cholesterol
(HDL-C), calculated low-density lipoprotein cholesterol
(LDL-C), calcium, phosphate, and creatinine. The last
follow-up visit was classified as motivated by new symptoms
for patients with symptomatic progression or as a systematic
follow-up for patients followed routinely without symptom-
atic progression. Complete drug treatment received could be
defined from all Olmsted County health care providers.
Echocardiographic methods. Comprehensive transtho-
racic echocardiograms were performed within a single echo-
cardiographic laboratory, with stable guidelines for Doppler
echocardiography whether patients had symptoms or not.
Immediate physician review (level III) allowed re-imaging
for quality control. Doppler of left ventricular outflow tract
and of aortic valve from multiple windows to obtain the
maximum velocity were recorded (20,21). This approach
provides accurate peak velocity, MG, and AVA using
continuity equation (21). All data were used as originally
reported.
Statistical analysis. Data are presented as mean  SD.
Group comparisons used t test, chi-square as appropriate.
Comparisons of baseline and follow-up data used paired t
test. Changes in MG, aortic peak velocity, dimensionless
index, and AVA were major end points for analysis. The
dimensionless index was the ratio of left ventricular outflow
tract velocity to aortic peak velocity. Changes in AS severity
were expressed as difference between baseline and follow-up
data, annualized rate of change, and percent annualized
change (proportion of baseline). Stepwise multiple linear
regression defined independent determinants of AS pro-
gression, and logistic regression defined odds ratios of
progression to specific thresholds. The association of statin
treatment with AS progression was adjusted for baseline
AVA and for age, gender, and other predictors of faster
progression. A value of p  0.05 was considered statistically
significant.
RESULTS
A total of 156 subjects made up the study population,
including 118 subjects who received no lipid-lowering
treatment during the follow-up period and 38 subjects who
took statins.
Untreated subjects. In 118 untreated subjects, age was 78
 12 years with 51% men. Most were asymptomatic;
dyspnea or chest pain was noted in only 3% and 7%,
respectively, but these symptoms were considered unrelated
to AS. Baseline characteristics are presented in the left
column of Table 1. Aortic stenosis was on average moderate
at baseline, with MG of 22  12 mm Hg and AVA of 1.20
 0.35 cm2. Atherosclerotic risk factors were highly prev-
alent, and TC level (214  45 mg/dl) showed a wide range
(122 to 391 mg/dl).
Progression of AS in untreated subjects. Repeated eval-
uation was motivated by new symptoms in 41 subjects
(35%), with dyspnea in 29, chest pain in 9, and both in 3.
Systematic follow-up was obtained in 77 patients (65%)
whose clinical status was unchanged.
Mean interval between echocardiograms was 3.7  2.3
years. Aortic MG increased from 22  12 mm Hg to 39 
Abbreviations and Acronyms
AS  aortic stenosis
AVA  aortic valve area
CI  confidence interval
HDL-C  high-density lipoprotein cholesterol
MG  mean gradient
LDL-C  low-density lipoprotein cholesterol
TC  total cholesterol
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19 mm Hg and AVA decreased from 1.20  0.35 cm2 to
0.92  0.33 cm2 (both p  0.01) (Table 2). Annualized
decrease in AVA was 0.09  0.17 cm2 per year or 7 
13% per year. Aortic stenosis progression was similar in 17
subjects with bicuspid valves and 101 subjects with degen-
erative valves: MG increased from 20 10 mm Hg to 41
21 mm Hg for bicuspid valves versus 22 13 mm Hg to 39
 19 mm Hg for degenerative valves (p  0.28), and AVA
decreased from 1.33  0.35 cm2 to 1.05  0.35 cm2
(change  0.28  0.34 cm2) versus 1.17  0.35 cm2 to
0.89  0.33 cm2 (change  0.28  0.29 cm2), respec-
tively (p  0.97). Follow-up duration (3.8  1.9 years vs.
3.7  2.4 years, p  0.85) and annualized change in AVA
(0.07  0.09 cm2 vs. 0.09  0.18 cm2/year; p  0.56),
even adjusted for body surface area (p  0.40), were also
similar.
Of potential predictors of AS progression, only baseline
AVA showed a significant correlation with change in AVA
(r0.30, p 0.01). There was weak correlation between
AVA decrease and serum calcium concentration (r  0.17,
p 0.07), which became insignificant adjusting for baseline
AVA (p  0.24).
Association of cholesterol levels with progression of
AS. Neither the direct difference in AVA between baseline
and follow-up (r  0.01, p  0.26) nor the annualized
change in AVA (r  0.01, p  0.88) correlated with TC
levels. Similarly, no correlation was observed for progression
of AS and LDL-C (direct difference, r  0.07, p  0.50;
annualized change, r  0.01, p  0.94). There was no
correlation of cholesterol level with other measures of AS
progression (MG, peak velocity, and dimensionless index),
even excluding bicuspid valves (all p  0.42).
There was no difference in annualized change in AVA
(0.09  0.19 cm2/year vs. 0.09  0.12 cm2/year,
respectively; p  0.40) according to TC level  or 200
mg/dl or according to LDL-C level  or 120 mg/dl (p 
0.29). Untreated subjects were also divided according to
quartiles of TC concentration (183, 183 to 207, 207 to
237, and 237 mg/dl). There was no relationship between
TC quartiles and annualized changes in MG, peak velocity,
or AVA unadjusted or adjusted for body surface area (Fig.
1). In fast-stenosis progressors (annualized AVA decrease
median or 0.07 cm2/year), neither TC (207  45 mg/dl
vs. 221  43 mg/dl, p  0.11) nor LDL-C (134  43
mg/dl vs. 142  43 mg/dl, p  0.45) differed from slower
Table 1. Baseline Characteristics of Patients With AS
Characteristic
Untreated
Group
(n  118)
Statin
Group
(n  38) p Value
Age, yrs 78  12 73  11 0.03
Gender, % men 51 55 0.64
Follow-up duration, yrs 3.7  2.3 3.7  2.1 0.94
Etiology, % bicuspid 14 18 0.56
Baseline AVA, cm2 1.20  0.35 1.32  0.29 0.04
Ejection fraction 0.57  0.14 0.56  0.13 0.66
Systolic blood pressure,
mm Hg
142  23 143  24 0.79
Diastolic blood pressure,
mm Hg
78  13 76  11 0.55
Total cholesterol, mg/dl 214  45 246  58  0.01
Triglyceride, mg/dl 129  68 171  104  0.01
LDL-C, mg/dl 137  43 164  49  0.01
HDL-C, mg/dl 49  16 45  12 0.21
Calcium, mg/dl 9.4  0.4 9.2  0.3 0.14
Creatinine, mg/dl 1.1  0.2 1.1  0.2 0.62
Hypertension, % 64 71 0.40
Diabetes mellitus, % 24 24 0.99
Coronary disease, % 26 63  0.01
Present smoker, % 11 13 0.72
Ever smoked, % 47 68 0.02
Continuous variables are indicated as means  SD.
AS  aortic stenosis; AVA  aortic valve area; HDL-C  high-density
lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol.
Table 2. Changes Between Baseline and Follow-Up in Patients With AS
Untreated Patients Statin-Treated Patients
Characteristic Baseline Follow-Up p* Baseline Follow-Up p*
Echocardiographic
LVOT velocity, m/s 1.0  0.2 1.0  0.2 0.35 1.0  0.2 1.0  0.2 0.69
Aortic peak velocity, m/s 3.0  0.8 3.9  1.0  0.01 2.8  0.5 3.4  0.7  0.01
Aortic mean gradient, mm Hg 22  12 39  19  0.01 18  7 27  12  0.01
Dimensionless index† 0.35  0.09 0.26  0.09  0.01 0.38  0.09 0.32  0.10  0.01
Aortic valve area, cm2 1.20  0.35 0.92  0.33  0.01 1.32  0.29 1.13  0.35  0.01
Aortic valve area, cm2/m2 0.66  0.19 0.50  0.19  0.01 0.71  0.17 0.60  0.20  0.01
Ejection fraction 0.57  0.14 0.56  0.14 0.32 0.56  0.13 0.56  0.12 0.85
Biochemical
Total cholesterol, mg/dl 214  45 198  42  0.01 246  58 207  54  0.01
Triglycerides, mg/dl 129  68 135  69 0.71 171  104 160  66 0.48
LDL-C, mg/dl 137  43 125  36  0.01 164  49 128  47  0.01
HDL-C, mg/dl 49  16 50  15 0.30 45  12 47  12 0.71
Calcium, mg/dl 9.4  0.4 9.2  0.5 0.38 9.2  0.3 9.3  0.4 0.90
Phosphate, mg/dl 3.4  0.5 3.5  0.6 0.42 3.4  0.6 3.3  0.5 0.41
Calcium-phosphate product, mg/dl 32  5 32  6 0.42 31  5 31  5 0.45
Creatinine, mg/dl 1.1  0.3 1.3  0.5 0.01 1.1  0.2 1.2  0.2 0.05
Continuous variables are indicated as means  1 SD. *p value is for paired t test within groups. †arbitrary units.
AS  aortic stenosis; HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; LVOT  left ventricular outflow tract.
1725JACC Vol. 40, No. 10, 2002 Bellamy et al.
November 20, 2002:1723–30 Cholesterol, Statins, and Progression of AS
progressors. Finally, there was no correlation between
follow-up (or difference baseline-follow-up) TC or LDL-C
and any measure of AS progression (all p  0.40).
Clinical atherosclerotic risk factors and progression of
AS. Hypertension, diabetes mellitus, smoking, and known
coronary disease showed no significant association with
higher annualized decrease in AVA (all p  0.12), decrease
in dimensionless index, increase in MG, or increase in peak
velocity. There was no difference between fast and slow AS
progressors regarding subjects with hypertension, diabetes
mellitus, smoking history, or known coronary disease (all
p  0.44).
Subjects treated with statins. Treated subjects were
slightly younger than those untreated, but they had more
prevalent risk factors and clinical coronary disease and
higher triglycerides, TC, and LDL-C (Table 1) as part of
the indication for statin treatment. Baseline AVA was also
slightly larger (p  0.04) in treated patients, a factor
associated with faster progression.
Follow-up was 3.7  2.1 years, identical to untreated
subjects (p 0.94), and the duration of statin treatment was
2.9  1.7 years (78%). The drugs used were mostly
simvastatin (n  13) or lovastatin (n  13). During
follow-up, TC and LDL-C decreased (both p  0.01,
Table 2). Comparing statin-treated with untreated patients,
follow-up TC (p  0.30) and LDL-C (p  0.78) were not
different, whereas triglycerides remained borderline higher
(160  66 mg/dl vs. 135  69 mg/dl, p  0.08).
Progression of AS in statin-treated subjects. New symp-
toms occurred in 7 patients (18%) (dyspnea in 4, chest pain
in 2, both in 1) and systematic follow-up was obtained in 31
subjects (82%) with unchanged clinical status.
There was AS progression with MG increasing (18  7
mm Hg to 27  12 mm Hg), peak velocity increasing (2.8
 0.5 m/s to 3.4  0.7 m/s), and AVA decreasing (1.32 
0.29 cm2 to 1.13  0.35 cm2, all p  0.01). Annualized
AVA decrease was 0.04  0.15 cm2/year or 3 10%/
year. Compared with untreated subjects and adjusting for
baseline AVA differences, statin-treated subjects had mark-
edly smaller annualized increase in peak velocity, decrease in
dimensionless index, and decrease in AVA (Table 3).
Defining AS progression as a decrease in AVA 5%/
year (group median), the odds ratio (Fig. 2, Table 3) of
progression with statin treatment was 0.46 (95% confidence
interval [CI], 0.21 to 0.96) and remained unchanged even
after adjustment for age, gender, and baseline AVA (odds
ratio, 0.46; 95% CI, 0.21 to 0.98).
There was no trend of association of TC or fractions at
baseline or follow-up with AS progression (all p  0.25).
Merging treated and untreated patients, there was no
correlation between the magnitude of decrease in TC or
LDL-C level and progression of stenosis. Comparing sub-
jects with follow-up TC decrease 5 mg/dl versus 5
mg/dl, there was no difference in annualized AVA decrease
(0.08  0.15 vs. cm2/year 0.07  0.10 cm2/year, p 
0.77). This result was similar stratifying for a decrease in
Figure 1. Annualized progression in mean gradient (Mean Grad), peak velocity (Vmax), and aortic valve area (AVA) by quartile of total cholesterol (TChol)
concentration in subjects not receiving lipid-lowering treatment. The circles and vertical bars indicate means and standard errors. BSA  body surface
area.
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LDL-C of 5 versus 5 mg/dl (p  0.70). Also, there was
no difference between rapid (AVA decrease 5%/year)
and slow progressors regarding follow-up triglycerides, TC,
HDL-C, and LDL-C levels (all p  0.60).
Statin treatment and AS progression in patients with
systematic follow-up. Patients with symptom increase
warranting follow-up examination presented with lower
AVA at baseline (1.1  0.36 cm2 vs. 1.28  0.32 cm2, p 
0.006) and follow-up (0.82  0.35 cm2 vs. 1.04  33 cm2,
p  0.001) and with larger MG increase (19  17 mm
Hg vs. 13  14 mm Hg, p  0.035) than patients
examined systematically. As increased symptoms were more
frequent in untreated patients (35% vs.18%, p  0.05), we
examined statin treatment effect in the 108 patients coming
for systematic follow-up.
In patients with systematic follow-up (n  108), statin-
treated (n 31) compared with untreated (n 77) patients
had an identical follow-up (p  0.98) and baseline AVA
(1.33  0.28 cm2 vs. 1.26  0.34 cm2, p  0.29) but less
AS progression. Mean gradient increase (8  9 mm Hg
vs.15 15 mm Hg, p 0.01) and AVA decrease (0.01
 015 cm2/year vs.0.09  0.19 cm2/year, p 0.04) were
slower in statin-treated patients. Odds ratio of AVA pro-
gression 5%/year in statin-treated patients was 0.34
(95% CI, 0.13 to 0.82; p  0.02) unadjusted (Fig. 2) and
0.31 (95% CI, 0.11 to 0.81; p  0.03) after adjustment for
age, gender, baseline cholesterol level, and AVA.
Subjects eligibility. As eligibility criteria may affect results,
we examined all patients with AS in Olmsted County. First,
patients without follow-up echocardiogram (n  583) did
not allow assessment of AS progression but had identical
baseline characteristics (age 75  13 years, MG 22  15
Table 3. Progression of Aortic Stenosis According to Statin Treatment
Variable
Untreated Group Statin Group
p A–P†
Criteria for
Yearly
Progression
Percent Change
Odds
Ratio* 95% CI
Absolute
Change
Yearly
%Change
Absolute
Change
Yearly
%Change
LVOT velocity, m/s 0.0  0.2 1  12 0.0  0.2 0  6 0.33 0.49 — — —
Aortic peak velocity, m/s 0.9  0.8 9  12 0.5  0.5 5  8 0.03 0.02 7 0.38 0.17–0.80
Aortic mean gradient,
mm Hg
17  16 24  29 9  9 16  19 0.05 0.05 19 0.42 0.19–0.90
Dimensionless index‡ 0.08  0.09 7  13 0.06  0.08 3  10 0.04 0.04 5 0.48 0.22–0.99
AVA, cm2 0.28  0.30 7  13 0.19  0.27 3  10 0.04 0.04 5 0.46 0.21–0.96
AVA/BSA, cm2/m2 0.15  0.17 7  13 0.10  0.15 3  10 0.04 0.05 5 0.48 0.22–0.99
Values are means 1 SD. P values are for comparison of percent change per year between untreated vs. statin groups. *Odds ratios apply for progression of statin-treated patients.
†A-P value pertaining to the association of statin treatment with slower progression, adjusted for age, gender, total cholesterol, and baseline aortic valve area. ‡Arbitrary units.
AVA  aortic valve area; AVA/BSA  aortic valve area per m2 of body surface area; LVOT  left ventricular outflow tract; %change  percent change of the variables.
Figure 2. Association of statin treatment with slower progression of aortic stenosis (AS) as shown by odds ratios and 95% confidence intervals1 for criteria
of progression. The odds ratios are indicated by the circles (for the overall population) and by squares (for patients with systematic follow-up [F-U] not
motivated by symptomatic progression) with their 95% confidence interval (continuous and dashed line, respectively). Progression criteria are defined by
median in the population for (top to bottom) mean gradient (Mean grad), peak transaortic velocity (Vmax), dimensionless index (Index), aortic valve area
(AVA), and aortic valve area standardized to body surface area (AVA/BSA). The directions of the changes are indicated by the arrows: upward for increases,
downward for decreases.
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mm Hg, AVA 1.26  0.40 cm2, and cholesterol 204  45
mg/dl), showing that our study population is representative
of all patients with AS. Second, a baseline cholesterol level
measurement is indispensable to assess cholesterol’s relation
to AS progression. Aortic stenosis progression was similar
in subjects without baseline cholesterol (n  47, 0.08 
0.17 cm2/year) and study patients. Third, lipid-lowering
treatment without statin was rarely taken (n  11) and
involved fibrate in seven patients, niacin in three, and
cholestyramine in one. In these subjects, changes in MG
(21  18 mm Hg), AVA (0.36  0.33 cm2), and
annualized AVA decline (0.13  0.05 cm2/year) were
similar to untreated patients (all p  0.40) despite a notable
LDL-C decrease (30  23 mg/dl, p  0.69 vs. statin
treatment).
To examine if limited power caused the lack of correla-
tion between TC and AS progression, we analyzed 729
patients with AS (without intervening AVR or endocardi-
tis) not from Olmsted County. Baseline AVA, MG, and
cholesterol (1.26  0.34 cm2, 22  11 mm Hg, 213  46
mg/dl, respectively) were similar to our study group, and
decline of AVA (0.08  0.19 cm2/year) was unrelated to
cholesterol level (r  0.01, p  0.81). Hence, increased
power does not affect results.
DISCUSSION
This study shows that in the community, over 3.7 years
during which most patients remain asymptomatic, there is
significant AS progression bringing average AVA from the
moderate to severe range. The progression is faster in
patients with larger baseline AVA. Despite mechanistic
association between cholesterol deposition and formation of
the early sclerotic lesion, AS progression is unrelated to
cholesterol level, total, or fractions. In contrast, AS progres-
sion is markedly slower in subjects receiving treatment with
statin drugs. This observation supports conducting a clinical
trial evaluating the hypothesis that statins reduce the rate of
progression of AS.
The cholesterol hypothesis of AS progression. Degen-
erative AS lesions involve calcifications of leaflets, which
become rigid and obstruct blood flow, and these lesions
differ from rheumatic ones (commissural fusion). The initial
lesion, valve sclerosis, is a deposition of lipids (22), which
are oxidized similarly to atherosclerosis (4). Also similar
to atherosclerosis, lipoproteins are present (3), with co-
localization of calcifications (22), which are actively regu-
lated (23). Not surprisingly, atherosclerotic risk factors are
frequent in patients with aortic sclerosis defined by echo-
cardiography (7) or by computed tomography (24). These
observations have been the basis for the cholesterol hypoth-
esis of AS and for the interest raised by the possibility for
medical treatment of a condition that has none.
However, AS and sclerosis are different: AS has over-
growth of calcium, which may have its own determinants
independent of cholesterol levels (25). Therefore, it is
important to analyze hyperlipidemia, not for its case-control
association with presence of valve sclerosis (7–9,12), but for
its temporal association with AS progression. Indeed, AS
progression is consistently observed (26), but at a variable
rate (27), and fast progression leads to poor outcome (15).
Studies linking AS progression and hyperlipidemia have
been unconvincing and contradictory (10,11,15). All were
limited by major referral bias. The largest “positive” study
found faster progression with cholesterol 200 mg/dl, but
overall showed strictly no correlation between cholesterol
and AS progression (10). In our community-based study,
with the longest available follow-up, we found that in
untreated subjects neither TC nor LDL-C levels predicted
AS progression. This lack of correlation between lipid levels
and AS progression was also confirmed using all possible
statistical approaches. Similarly, other atherosclerotic risk
factors were not associated with AS progression.
Thus, although AS starts as an atherosclerotic process, as
shown in our community by the association of aortic
sclerosis and atherosclerosis (28), severity of atherosclerotic
risk factors, particularly cholesterol level, does not affect AS
progression measurably (10). However, this observation
should not be taken to suggest that mechanistic anti-
atherosclerotic treatment of AS should not be tested.
Indeed, in vascular atherosclerosis cholesterol levels corre-
late poorly to anatomic progression of disease (29,30).
Nevertheless, statin treatment improves anatomic athero-
sclerotic lesions (31) and considerably improves clinical
outcome even in patients without hyperlipidemia. Using
that similarity, it is crucial to analyze the statin treatment
effect on AS progression.
Pleiotropic effects of statins. The suggested effect of
statins in reducing AS progression (6,17) stems from the
mechanistic similarities between atherosclerosis and AS.
However, this effect may be overestimated because of
confounding association with renal failure. Importantly,
referral bias in general, and particularly related to hyperlip-
idemia and frequent coronary disease in patients treated
with statins, may lead to spurious effects. Repeated exami-
nation, indispensable for assessment of AS progression, may
be misleading, as patients returning for systematic evalua-
tion of hyperlipidemia have a less severe and less progressive
AS than patients returning for symptomatic AS progres-
sion. This raises concerns that stated statin effects may be
overestimated (6,17). Therefore, focusing on community
patients rather than on those distantly referred to major
centers, prospectively recording therapies, and confirming
observations among patients systematically evaluated are
essential steps in linking statins to reduced AS progression.
Indeed, despite unassociated cholesterol levels and AS
progression, statin-treated patients demonstrate much
slower AS progression, with odds ratio of progression
between 0.38 and 0.48. No other treatment showed a trend
for such a preventive effect. This observation does not
replace randomized clinical trials in establishing therapeutic
effects of statins in AS, but is a seminal and strong
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suggestion that a trial is warranted in patients with and
without hyperlipidemia, as AS progresses equally fast in
both groups. The observation that AS progression is unre-
lated to cholesterol levels but is markedly slowed by
cholesterol-lowering treatment is challenging and raises
questions about potential mechanisms of this effect.
Aortic stenosis formation and progression is complex
and, although called “degenerative,” is active. Lipoprotein
deposition, aortic valvular inflammation (22), and simulta-
neous calcification and ossification (23,32,33) are involved.
Indeed, AS is an inflammatory disease where excess tissue
valvular adhesion molecules (34), metalloproteinase (35),
and tenascin (36) link local inflammatory process and
development of the hemodynamic valvular lesion. Further-
more, elevated blood levels of E-selectin (34), C-reactive
protein (37), and tumor necrosis factor (38) demonstrate
systemic inflammation in AS. In turn, active inflammation,
even without overt hyperlipidemia, may be associated with
increased disease risk, similar to atherosclerosis (39).
Statins have pleiotropic effects, including anti-
inflammatory effects (40), with reduction of C-reactive
protein independent of lipid changes (41). Statins depress
leukocyte cell surface molecules required for monocyte
adhesion and initiation of inflammation (42). Statins retard
extra-osseous calcifications, as for coronary vessels (43),
while they improve osseous calcifications, protect against
bone fracture (44), stimulate bone morphogenetic protein
production and increase bone formation (45). More research
is needed, but one can propose that statins’ benefit may be
related in part to their particular pleiotropic effects, anti-
inflammatory together with stabilization of the early aortic
valve lesion, retarding ossification and calcification.
Potential limitations. Echocardiographic assessment may
have limitations but has been proven to be reliable and
reproducible in our institution (20,21), and is now the main
method on which surgical decisions are based in AS.
Furthermore, dimensionless index, independent of annulus
diameter, provided similar results to those obtained with
AVA.
The degree of obstruction qualifying as AS is not well
defined (2). However, patients with mildest baseline ob-
struction (MG 10 mm Hg to 20 mm Hg) progressed
markedly (MG 14  3 mm Hg to 30  15 mm Hg, p 
0.001; AVA changed by 0.32  0.04 cm2 vs. 0.22 
0.04 cm2 in patients with more severe AS, p  0.10),
showing that AS progression in these patients may lead to
severe stenosis and should be prevented.
Our community study was powered to detect a correla-
tion coefficient of r  0.22. Lack of association between
cholesterol and AS progression was supported by trends for
greater progression with lowest cholesterol (Fig. 1) and by
results in noncommunity patients, showing that with in-
creased power, results are unchanged.
Conclusions. In our community, AS progression is unaf-
fected by hyperlipidemia, cholesterol levels, or other athero-
sclerosis risk factors. Statin treatment, however, is associated
with slower progression, suggesting an independent bene-
ficial effect. This seminal observation supports the proposal
for a clinical trial of statins in degenerative AS across the
range of cholesterol concentrations.
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